New hope for hard-to-treat cancers: experimental drug PEP08 targets MTAP-deleted tumors

NCT ID NCT06973863

Recruiting now Disease control Sponsor: PharmaEngine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 29 times

Summary

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 40 adults will receive PEP08 alone or with another cancer drug, and researchers will monitor side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Medical University Hospital
RECRUITING

Taichung, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan
Westmead Hospital
RECRUITING

Wentworthville, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR MTAP DELETION MTAP-DELETED SOLID TUMORS SOLID TUMORS SOLID TUMORS